SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MIKE DUBIS who wrote (3027)12/4/1997 6:55:00 AM
From: RT  Read Replies (1) of 23519
 
Mike,

VIVUS GETS NO RESPECT!
When you factor in estimated 4Q earnings Vivus will be selling at a PE of 17.
The industry's average PE is 43 !!
It's apparent investors are concerned about Vivus's ability to maintain or expand it's market once Viagara hits the market.

I personally see little downside risk at this point but I won't expect any major move past the low 30's until after Viagara is launched and Vivus proves it's still a major player.
Vivus will always be viewed with a bit of skepticism as long as it's a one product company. They are too vulnerable and need to expand their product line beyond muse.

In the meantime, will just have to wait and see.

Still a Believer,
RT
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News